108.40
-1.09%
Close of 9 Nov 2026, in CHF
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Medartis Holding
Its shares trade on SIX under the ticker MED.SW. It has been listed since 23 March 2018. In the fiscal year to 31 December 2025, it reported revenue of CHF 269.3m and net income of CHF 8.3m. At that date it held total assets of CHF 559.9m and shareholders' equity of CHF 275.9m.
Medartis Holding AG is a medical device company, which engages in the development, manufacture, and sale of implant solutions for internal surgical fixation, through its subsidiaries. The company is headquartered in Basel, Basel-Stadt. The company went IPO on 2018-03-23. The Group develops, manufactures and distributes to surgeons, hospitals and medical centers titanium screws, plates, surgical instruments and system solutions for internal fracture fixation. Medartis AG, the Company's wholly-owned subsidiary, has developed such technologies as TriLock for locking the screw into the plate, SpeedTip, a screw that does not require pre-drilling, and HexaDrive self-holding screw and screw-driver. The company has two product lines. The APTUS product line comprises upper and lower extremities products for hand, wrist, elbow, shoulder and foot fixation. The MODUS line combines products dedicated to cranio-maxillofacial (CMF) surgery. The Group's products are sold globally in more than 30 countries, including Germany and the United States, either directly through its sales subsidiaries, or through third-party distributors.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 23 Mar 2018
- Employees
- 636
- Website
- medartis.com ↗
Leadership
Pay as last reported
- Mr. Marco GadolaNon-Executive Independent Chairman of the BoardCHF 535,280
- Mr. Matthias SchuppChief Executive Officer, Member of the Executive Management BoardCHF 868,699
- Dr. H. C. StraumannNon-Executive Vice Chairman of the Board, since 1998CHF 292,061
- Dr. Dirk KirstenChief Financial Officer, Member of the Executive Management Board
- Mr. Mario Della CasaChief Operating Officer, Member of the Executive Management Board
- Ms. Inge MaesChief Human Resource Officer, Member of the Executive Management Board
- Mr. Manuel SchaerChief Technology Officer, Member of the Executive Management Board
- Ms. Mareike LochPresident - EMEA, Member of the Executive Management Board
- Mr. David ThoniUS President, Member of the Executive Management Board
- Ms. Jennifer DeanNon-Executive Independent Member of the BoardCHF 107,830
- Mr. Willi MieschNon-Executive Independent Member of the Board, since 1998CHF 161,725
- Mr. Ciro RoemerNon-Executive Independent Member of the BoardCHF 150,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 83
- Environment
- 96
- Social
- 99
- Governance
- 53
- Direct emissions (scope 1)
- 877.1 t
- Energy emissions (scope 2)
- 752.45 t
- Value chain emissions (scope 3)
- 5,788.86 t
- Women in the workforce
- 42%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Leading position in the market: Medartis Holding AG is a well-established company with a strong presence in the medical devices industry.
- Broad product portfolio: The company offers a wide range of innovative and high-quality surgical solutions, catering to various medical specialties.
- Strong research and development capabilities: Medartis invests significantly in R&D to develop new products and improve existing ones, ensuring its competitiveness in the market.
Weaknesses
- Dependence on a limited number of markets: Medartis relies heavily on European and North American markets for its revenue, making it susceptible to any fluctuations or economic uncertainties in these regions.
- Relatively high pricing: The premium quality and advanced technology of Medartis' products often lead to higher prices, which may limit accessibility for price-sensitive markets.
- Limited brand recognition outside medical professionals: The company's brand awareness among the general public is relatively low, which may hinder its growth potential.
Opportunities
- Emerging markets: Medartis can explore and expand its presence in the growing economies of Asia, Latin America, and other regions, where there is increasing demand for medical devices.
- Technological advancements: The continuous advancements in surgical techniques and materials present opportunities for Medartis to develop and introduce innovative products.
- Acquisitions and partnerships: The company can consider strategic collaborations or acquisitions to enhance its product offerings, enter new markets, or strengthen its market position.
Threats
- Intense competition: Medartis faces competition from both established and emerging players in the medical devices market, which may impact its market share and pricing power.
- Stringent regulations: The medical devices industry is subject to strict regulations and compliance requirements, which may increase costs and pose challenges in product development and commercialization.
- Economic uncertainties: Macro-economic factors such as recessions or global economic downturns can adversely impact healthcare spending and affect Medartis' revenue.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.